Aspire Biopharma Holdings, Inc. operates as a biopharmaceutical company that engages in developing and marketing a disruptive technology for drugs, nutraceuticals & supplements. The company develops and markets a technology for novel delivery mechanisms for FDA approved drugs, nutraceuticals, and supplements. The company has developed and acquired technologies that are a Novel Soluble Formulation which address emergencies and drug efficacy, dosage management, and response time. Its Sublingual Aspirin Product, which addresses cardiology emergencies and pain management, is a granular or powder formulation of a soluble, Ph-neutral, fast-acting aspirin. The company also has numerous pharmaceutical and nutraceutical applications under development in various areas, including but not limited to a Viagra/Cialis combination product which is faster acting, requiring decreased dosages with the benefit of a longer half-life, various bi-hormonal drugs such as testosterone, estrogen and weight loss drugs, and thyroid drugs, as well as various supplements including a rapid-absorbing pre-workout and a melatonin sleep aid.
ASBP stock price ended at $2.21 on 金曜日, after rising 4320.00%
On the latest trading day Jan 16, 2026, the stock price of ASBP rose by 4320.00%, climbing from $1.96 to $2.21. Throughout the session, the stock experienced a volatility of 35.76%, with prices fluctuating between a daily low of $1.65 and a high of $2.24. Alongside this price increase, trading volume also rose by 28.7M shares, reflecting strong market interest that may signal continued bullish momentum in the near term. In total, 1.1M shares were traded, amounting to a market value of approximately $237.5M.